Causes of erectile dysfunction in non-alcoholic fatty liver disease.
Erectile dysfunction
International Index of Erectile Function
fatty liver
non-alcoholic fatty liver disease
Journal
Hepatology forum
ISSN: 2757-7392
Titre abrégé: Hepatol Forum
Pays: Turkey
ID NLM: 9918351171306676
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
12
04
2021
accepted:
05
05
2021
entrez:
5
7
2022
pubmed:
24
5
2021
medline:
24
5
2021
Statut:
epublish
Résumé
Erectile dysfunction (ED) is an important and commonly seen disorder in patients with non-alcoholic fatty liver disease (NAFLD). The objective of this study was to assess the rate of ED and its causes in a group of NAFLD patients. The International Index of Erectile Function questionnaire (IIEF-5) was used to evaluate the presence, causes, and severity of ED. Participants with an IIEF-5 score of <22 who agreed to undergo a urological evaluation were referred to a urologist for further assessment. A total of 136 NAFLD patients were enrolled in the study. According to the IIEF-5, 68 (50.0%) patients had ED. Multivariate analysis indicated that older age, obesity, and hypertension were associated with ED. Seventeen patients had multiple etiological factors for ED. Psychogenic ED was identified in 19 patients (39.6%), vasculogenic ED in 35 patients (72.9%), drug-related ED in 3 patients (6.3%), and neurogenic ED in 6 patients (12.5%). ED is frequently seen in NAFLD patients, which may, at least in part, be due to common risk factors. Vasculogenic dysfunction is the most common single source of ED in NAFLD patients. Nonetheless, all potential etiologies should be carefully investigated, with special attention given to psychogenic factors, since they may be more frequent and relevant than expected.
Sections du résumé
Background and Aim
UNASSIGNED
Erectile dysfunction (ED) is an important and commonly seen disorder in patients with non-alcoholic fatty liver disease (NAFLD). The objective of this study was to assess the rate of ED and its causes in a group of NAFLD patients.
Materials and Methods
UNASSIGNED
The International Index of Erectile Function questionnaire (IIEF-5) was used to evaluate the presence, causes, and severity of ED. Participants with an IIEF-5 score of <22 who agreed to undergo a urological evaluation were referred to a urologist for further assessment.
Results
UNASSIGNED
A total of 136 NAFLD patients were enrolled in the study. According to the IIEF-5, 68 (50.0%) patients had ED. Multivariate analysis indicated that older age, obesity, and hypertension were associated with ED. Seventeen patients had multiple etiological factors for ED. Psychogenic ED was identified in 19 patients (39.6%), vasculogenic ED in 35 patients (72.9%), drug-related ED in 3 patients (6.3%), and neurogenic ED in 6 patients (12.5%).
Conclusion
UNASSIGNED
ED is frequently seen in NAFLD patients, which may, at least in part, be due to common risk factors. Vasculogenic dysfunction is the most common single source of ED in NAFLD patients. Nonetheless, all potential etiologies should be carefully investigated, with special attention given to psychogenic factors, since they may be more frequent and relevant than expected.
Identifiants
pubmed: 35783901
doi: 10.14744/hf.2021.2021.0012
pii: hf-2-60
pmc: PMC9138920
doi:
Types de publication
Journal Article
Langues
eng
Pagination
60-63Informations de copyright
© Copyright 2021 by Hepatology Forum - Available online at www.hepatologyforum.org.
Déclaration de conflit d'intérêts
Conflict of Interest: The authors have no conflict of interest to declare.
Références
J Hepatol. 2010 Aug;53(2):372-84
pubmed: 20494470
J Endocrinol Invest. 2010 Jul-Aug;33(7):501-5
pubmed: 20671409
J Sex Med. 2016 Mar;13(3):383-8
pubmed: 26853046
Eur J Gastroenterol Hepatol. 2015 Sep;27(9):1069-73
pubmed: 26062079
Hepatology. 2018 Jan;67(1):328-357
pubmed: 28714183
J Sex Med. 2010 Nov;7(11):3572-88
pubmed: 21040491
Arch Intern Med. 2006 Jan 23;166(2):207-12
pubmed: 16432090
Diabetes Metab. 2020 Sep;46(4):288-295
pubmed: 31786360
Sex Med Rev. 2020 Apr;8(2):274-285
pubmed: 30898592
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20
pubmed: 28930295
J Hepatol. 2016 Jun;64(6):1388-402
pubmed: 27062661
Clin Gastroenterol Hepatol. 2019 Feb;17(3):543-550.e2
pubmed: 30012432
Arch Ital Urol Androl. 2014 Sep 30;86(3):197-201
pubmed: 25308583
Curr Diab Rep. 2021 Mar 19;21(5):15
pubmed: 33742318
Atherosclerosis. 2019 Nov;290:222-223
pubmed: 31492444
Int J Impot Res. 1999 Dec;11(6):319-26
pubmed: 10637462
Am J Med. 2007 Feb;120(2):151-7
pubmed: 17275456
Arab J Gastroenterol. 2017 Mar;18(1):21-24
pubmed: 28325476
J Gastroenterol Hepatol. 2019 Nov;34(11):2011-2018
pubmed: 31115065